Insmed Incorporated (NASDAQ:INSM) Shares Bought by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. lifted its stake in Insmed Incorporated (NASDAQ:INSM - Free Report) by 74.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 33,052 shares of the biopharmaceutical company's stock after buying an additional 14,110 shares during the period. China Universal Asset Management Co. Ltd.'s holdings in Insmed were worth $2,413,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. V Square Quantitative Management LLC purchased a new stake in shares of Insmed in the 3rd quarter valued at about $30,000. EntryPoint Capital LLC purchased a new stake in Insmed in the first quarter valued at approximately $33,000. Fidelis Capital Partners LLC acquired a new stake in shares of Insmed in the first quarter valued at approximately $34,000. GAMMA Investing LLC grew its position in shares of Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company's stock worth $39,000 after acquiring an additional 224 shares during the last quarter. Finally, First Horizon Advisors Inc. increased its holdings in shares of Insmed by 83.4% in the 2nd quarter. First Horizon Advisors Inc. now owns 631 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 287 shares during the period.

Analysts Set New Price Targets

INSM has been the topic of several research reports. TD Cowen raised their price objective on shares of Insmed from $75.00 to $98.00 and gave the stock a "buy" rating in a research report on Friday, August 9th. Morgan Stanley upped their price objective on Insmed from $60.00 to $85.00 and gave the company an "overweight" rating in a research note on Friday, July 12th. Bank of America boosted their target price on Insmed from $84.00 to $86.00 and gave the company a "buy" rating in a report on Wednesday, October 9th. Stifel Nicolaus increased their price target on Insmed from $74.00 to $88.00 and gave the stock a "buy" rating in a report on Friday, August 9th. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Insmed from $72.00 to $74.00 and gave the company an "overweight" rating in a research note on Thursday, October 3rd. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. Based on data from MarketBeat, Insmed has an average rating of "Moderate Buy" and an average price target of $82.73.

Insider Activity at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm's stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the sale, the insider now owns 100,100 shares in the company, valued at $7,157,150. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In related news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the business's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total value of $2,686,612.50. Following the completion of the sale, the insider now directly owns 100,100 shares in the company, valued at approximately $7,157,150. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Martina M.D. Flammer sold 13,436 shares of Insmed stock in a transaction on Monday, September 16th. The shares were sold at an average price of $74.92, for a total transaction of $1,006,625.12. Following the completion of the transaction, the insider now owns 106,134 shares in the company, valued at approximately $7,951,559.28. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 78,882 shares of company stock valued at $5,765,446 over the last quarter. Insiders own 4.60% of the company's stock.

Insmed Price Performance

NASDAQ INSM traded down $1.01 during trading hours on Tuesday, reaching $70.95. The company's stock had a trading volume of 1,047,055 shares, compared to its average volume of 2,285,059. The company has a debt-to-equity ratio of 25.05, a quick ratio of 2.53 and a current ratio of 2.71. The stock has a market cap of $10.54 billion, a PE ratio of -13.57 and a beta of 1.11. The company's 50-day moving average is $73.72 and its two-hundred day moving average is $60.56. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $80.53.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($1.94) earnings per share for the quarter, missing analysts' consensus estimates of ($1.22) by ($0.72). The firm had revenue of $90.34 million for the quarter, compared to analyst estimates of $87.95 million. Insmed's quarterly revenue was up 17.0% on a year-over-year basis. During the same period last year, the business posted ($1.78) earnings per share. Analysts forecast that Insmed Incorporated will post -5.41 EPS for the current year.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.